bpiq-i

BPIQ-I (PD 159121) is a potent and ATP-competitive EGFR tyrosine kinase inhibitor. BPIQ-I (PD 159121) shows anti-proliferative activity in EGFR-associated signaling models. BPIQ-I (PD 159121) is used in kinase inhibition research to study ATP-binding competition, EGFR pathway modulation, and downstream proliferative signaling regulation in cancer cell line experimental systems.

BPIQ-II is a linear imidazoloquinazoline that potently inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR; IC50 = 8 pM). It is selective for EGFR over other tyrosine and serine/threonine kinases, and cellular studies show that BPIQ-II can selectively inhibit EGF-stimulated signal transmission by competitively binding at the ATP site of EGFR.